HIV-associated neurocognitive disorder

The Lancet Infectious Diseases

Volumn 13, Issue 11, 2013, Pages 976-986

  Clifford, David B ^a   Ances, Beau M ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD163 ANTIGEN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHOLINE; CREATINE; IMMUNOGLOBULIN G; INTEGRASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; MEMANTINE; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYLASPARTIC ACID; NEOPTERIN; VALPROIC ACID; VIRUS DNA; VIRUS RNA;

ADJUVANT THERAPY; AGING; ANTIVIRAL THERAPY; ARTERIAL WALL THICKNESS; BLOOD BRAIN BARRIER; BOLD SIGNAL; BRAIN BLOOD FLOW; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CLINICAL FEATURE; COGNITIVE DEFECT; CONFUSION; DEVELOPED COUNTRY; DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA DETERMINATION; EXECUTIVE FUNCTION; FLUENCY DISORDER; FRACTIONAL ANISOTROPY; FUNCTIONAL DISEASE; FUNCTIONAL NEUROIMAGING; FUNCTIONAL STATUS; GLOMERULUS FILTRATION RATE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFLAMMATION; LUMBAR PUNCTURE; MEMORY DISORDER; MENTAL DETERIORATION; MONOCYTE; MONONUCLEAR CELL; MOTOR PERFORMANCE; MULTICENTER STUDY (TOPIC); NEUROIMAGING; NEUROPSYCHOLOGY; NEUROTROPISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE MEMORY; PSYCHOMETRY; REVIEW; RNA ANALYSIS; SELF REPORT; SEROCONVERSION; VIRAL CLEARANCE; VIRUS CONCENTRATION; VIRUS LOAD;

EID: 84886917428     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70269-X     Document Type: Review

References (160)

1. Harrison MJG, McArthur JC AIDS and neurology 1995, Churchill Livingstone, Edinburgh.
2. Hogg RS, Althoff KN, Samji H, et al. Increases in life expectancy among treated HIV-positive individuals in the United States and Canada, 2000-2007. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Kuala Lumpur, Malaysia; June 30-July 3, 2013. Abstract TUPE260.
3. McArthur JC, Steiner J, Sacktor N, Nath A Human immunodeficiency virus-associated neurocognitive disorders mind the gap. Ann Neurol 2010, 67:699-714.
4. Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 2011, 25:561-575.
5. Spudich S, Gonzalez-Scarano F HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med 2012, 2:a007120.
6. Churchill M, Nath A Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS 2013, 8:165-169.
7. Valcour V, Sithinamsuwan P, Letendre S, Ances B Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 2011, 8:51-60.
8. Tan IL, McArthur JC HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs 2012, 26:123-134.
9. Kranick SM, Nath A Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy. Continuum 2012, 18:1319-1337.
10. Harrison TB, Smith B Neuromuscular manifestations of HIV/AIDS. J Clin Neuromuscul Dis 2011, 13:68-84.
11. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010, 24:1243-1250.
12. Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. CHARTER study. Neurology 2010, 75:2087-2096.
13. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
14. Snider WD, Simpson DM, Nielsen S, Gold JWM, Metroka CE, Posner JB Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983, 14:403-418.
15. Navia BA, Jordan BD, Price RW The AIDS dementia complex: I. Clinical features. Ann Neurol 1986, 19:517-524.
16. Navia BA, Cho ES, Petito CK, Price RW The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986, 19:525-535.
17. Petito CK, Cho ES, Lemann W, Navia BA, Price RW Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J Neuropathol Exp Neurol 1986, 45:635-646.
18. Glass JD, Fedor H, Wesselingh SL, McArthur JC Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995, 38:755-762.
19. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990, 28:556-560.
20. 2-microglobulin in HIV-1 dementia. Neurology 1992, 42:1707-1712.
21. Wesselingh SL, Power C, Glass JD, et al. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 1993, 33:576-582.
22. Johnson RT, Glass JD, McArthur JC, Chesebro BW Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome. Ann Neurol 1996, 39:392-395.
23. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997, 42:689-698.
24. Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 1997, 42:679-688.
25. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011, 17:3-16.
26. Gisslen M, Price RW, Nilsson S The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?. BMC Infect Dis 2011, 11:356.
27. Lawton MP, Brody EM Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179-186.
28. Gandhi NS, Skolasky RL, Peters KB, et al. A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. J Neurovirol 2011, 17:159-165.
29. Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology 2007, 69:2213-2220.
30. Heaton R, Deutsch R, Franklin D, et al, for the CHARTER Group. Prevalence and predictors of neurocognitive decline over 18 to 42 months: a CHARTER longitudinal study. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; March 5-8, 2012. Abstract 246.
31. Clifford DB, McArthur JC, Schifitto G, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 2002, 59:1568-1573.
32. Evans SR, Yeh T, Sacktor N, et al. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 2007, 8:437-446.
33. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007, 69:1314-1321.
34. Clifford DB, Evans S, Yang Y, et al. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clinical Trials 2009, 10:343-355.
35. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009, 23:1359-1366.
36. Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 2011, 77:1135-1142.
37. Schmitt FA, Bigley JW, McKinnis R, et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988, 319:1573-1578.
38. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol 1993, 33:343-349.
39. Woods SP, Weber E, Weisz BM, Twamley EW, Grant I Prospective memory deficits are associated with unemployment in persons living with HIV infection. Rehabil Psychol 2011, 56:77-84.
40. Jacqueline H, Jenny WT, Jean-Paul F, et al. A diffusion tensor imaging and neuropsychological study of prospective memory impairment in South African HIV positive individuals. Metab Brain Dis 2012, 27:289-297.
41. Valcour VG Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools. Top Antivir Med 2011, 19:175-180.
42. Yarchoan R, Brouwers P, Spitzer AR, et al. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet 1987, 329:132-135.
43. Ellis R, Robertson K, Moo L, et al. NARC007: clinical validation of the AACTG neuroscreen. 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 8-11, 2004. Abstract 242.
44. Overton ET, Kauwe JS, Paul R, et al. Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav 2011, 15:1902-1909.
45. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005, 19:1367-1374.
46. Overton ET, Azad TD, Parker N, et al. The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. J Neurovirol 2013, 19:109-116.
47. Chalermchai T, Valcour V, Sithinamsuwan P, et al. Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. J Neurovirol 2013, 19:137-143.
48. Ellis RJ, Evans SR, Clifford DB, et al. Clinical validation of the neuroscreen. J Neurovirol 2005, 11:503-511.
49. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013, 56:1004-1017. Mind Exchange Working Group.
50. Cysique LA, Franklin DJ, Abramson I, et al. Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol 2011, 33:505-522.
51. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009, 73:1292-1299.
52. Wright EJ, Grund B, Robertson K, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010, 75:864-873.
53. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011, 25:1747-1751.
54. Valcour V, Yee P, Williams AE, et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection-the Hawaii aging with HIV cohort. J Neurovirol 2006, 12:387-391.
55. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 2008, 24:1301-1307.
56. Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011, 25:357-365.
57. Crum-Cianflone NF, Moore DJ, Letendre S, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology 2013, 80:371-379.
58. Lyons JL, Uno H, Ancuta P, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 2011, 57:371-379.
59. Valcour VG, Shiramizu BT, Sithinamsuwan P, et al. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort. The SEARCH 001 Cohort Study. Neurology 2009, 72:992-998.
60. Shiramizu B, Williams AE, Shikuma C, Valcour V Amount of HIV DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1-associated neurocognitive disorders. J Neuropsychiatry Clin Neurosci 2009, 21:68-74.
61. Valcour VG, Shiramizu BT, Shikuma CM HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukocyte Biol 2010, 87:621-626.
62. Shiramizu B, Ananworanich J, Chalermchai T, et al. Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. J Neurovirol 2012, 18:69-73.
63. Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS Unique monocyte subset in patients with AIDS dementia. Lancet 1997, 349:692-695.
64. Kusdra L, McGuire D, Pulliam L Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia. AIDS 2002, 16:31-38.
65. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC Elevated sCD163 is a marker of neurocognitive impairment in HIV infection. AIDS 2013, 27:1387-1395.
66. Burdo TH, Lackner A, Williams KC Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev 2013, 254:102-113.
67. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008, 3:e2516.
68. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
69. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 2012, 78:485-492.
70. Soulié C, Tubiana R, Simon A, et al. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr 2009, 51:60-64.
71. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010, 50:773-778.
72. Wendel KA, McArthur JC Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis 2003, 37:1107-1111.
73. Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluiud of subjects on suppressive antiretroviral treatment. J Infect Dis 2010, 202:1819-1825.
74. Bingham R, Ahmed N, Rangi P, Johnson M, Tyrer M, Green J HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape. Int J STD AIDS 2011, 22:608-609.
75. Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 2012, 26:1765-1774.
76. Power C, McArthur JC, Johnson RT, et al. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus Type 1 envelope sequences. J Virol 1994, 68:4643-4649.
77. Mishra M, Vetrivel S, Siddappa NB, Ranga U, Seth P Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 2008, 63:366-376.
78. Clifford DB, Mitike MT, Mekonnen Y, et al. Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. J Neurovirol 2007, 13:67-72.
79. Choi JY, Hightower GK, Wong JK, et al. Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol 2012, 18:81-90.
80. Dunfee RL, Thomas ER, Gorry PR, et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci USA 2006, 103:15160-15165.
81. Dunfee RL, Thomas ER, Wang J, Kunstman K, Wolinsky SM, Gabuzda D Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology 2007, 367:222-234.
82. Olivieri KC, Agopian KA, Mukerji J, Gabuzda D Evidence for adaptive evolution at the divergence between lymphoid and brain HIV-1 nef genes. AIDS Res Hum Retroviruses 2010, 26:495-500.
83. Sacktor N, Nakasujja N, Skolasky RL, et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 2009, 49:780-786.
84. Joseph J, Achim CL, Boivin MJ, et al. Global NeuroAIDS roundtable. J Neurovirol 2013, 19:1-9.
85. Everall I, Vaida F, Khanlou N, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 2009, 15:360-370.
86. Gelman BB, Lisinicchia JG, Morgello S, et al. Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr 2013, 62:487-495.
87. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007, 196:1779-1783.
88. Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr 2012, 60:234-243.
89. Gray F, Lescure FX, Adle-Biassette H, et al. Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol 2013, 23:525-533.
90. Riedel DJ, Pardo CA, McArthur JC, Nath A Therapy insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol 2006, 2:557-565.
91. Langford TD, Letendre SL, Marcotte TD, et al. Severe, demyelinating leukoencepahlopathy in AIDS patients on antiretroviral therapy. AIDS 2002, 16:1019-1029.
92. Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ, Gisslén M Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology 2007, 69:1536-1541.
93. Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL)-a marker of active HIV-related neurodegeneration. J Neurol 2007, 254:1026-1032.
94. Gisslén M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L Elevated cerebrospinal fluiud neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 2007, 195:1774-1778.
95. Gisslén M, Krut J, Andreasson U, et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 2009, 9:63.
96. Letendre S, Rosario D, Ellis R, Potter M, Woods SP. Higher levels of phosphorylated tau in CSF are associated with HIV infection, older age, antiretroviral use, and worse prospective memory. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 3, 2011. Abstract 222.
97. Ellis RJ, Seubert P, Motter R, et al. Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. Neurosci Lett 1998, 254:1-4.
98. Clifford DB, Fagan AM, Holtzman DM, et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009, 73:1982-1987.
99. Cysique LA, Moffat K, Moore DM, et al. HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study. PLoS One 2013, 8:e61738.
100. Lentz MR, Kim WK, Kim H, et al. Alterations in brain metabolism during the first year of HIV infection. J Neurovirol 2011, 17:220-229.
101. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011, 25:625-633.
102. Descamps M, Hyare H, Stebbing J, Winston A Magnetic resonance imaging and spectroscopy of the brain in HIV disease. J HIV Ther 2008, 13:55-58.
103. Cohen RA, Harezlak J, Gongvatana A, et al. Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol 2010, 16:435-444.
104. Chang L, Ernst T, Witt MD, et al. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther 2003, 8:17-26.
105. Rottenberg DA, Moeller JR, Strother SC, et al. The metabolic pathology of the AIDS dementia complex. Ann Neurol 1987, 22:700-706.
106. Venneti S, Lopresti BJ, Wang G, et al. PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. J Clin Invest 2004, 113:981-989.
107. Garvey LJ, Pavese N, Politis M, et al. Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART; an 11C-PK11195 PET study. AIDS 2013, published online July 24. 10.1097/01.aids.0000432467.54003.f7.
108. Wiley CA, Lopresti BJ, Becker JT, et al. Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. J Neurovirol 2006, 12:262-271.
109. Heaps JM, Joska J, Hoare J, et al. Neuroimaging markers of human immunodeficiency virus infection in South Africa. J Neurovirol 2012, 18:151-156.
110. Thompson PM, Dutton RA, Hayashi KM, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci USA 2005, 102:15647-15652.
111. Jernigan TL, Archibald SL, Fennema-Notestine C, et al. Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol 2011, 17:248-257.
112. Ances BM, Ortega M, Vaida F, Heaps J, Paul R Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr 2012, 59:469-477.
113. Fennema-Notestine C, Ellis RJ, Archibald SL, et al. Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol 2013, 19:393-401.
114. Wu Y, Storey P, Cohen BA, Epstein LG, Edelman RR, Ragin AB Diffusion alterations in corpus callosum of patients with HIV. AJNR Am J Neuroradiol 2006, 27:656-660.
115. Nakamoto BK, Jahanshad N, McMurtray A, et al. Cerebrovascular risk factors and brain microstructural abnormalities on diffusion tensor images in HIV-infected individuals. J Neurovirol 2012, 18:303-312.
116. Wright PW, Heaps JM, Shimony JS, Thomas JB, Ances BM The effects of HIV and combination antiretroviral therapy on white matter integrity. AIDS 2012, 26:1501-1508.
117. Gongvatana A, Cohen RA, Correia S, et al. Clinical contributors to cerebral white matter integrity in HIV-infected individuals. J Neurovirol 2011, 17:477-486.
118. Melrose RJ, Tinaz S, Castelo JM, Courtney MG, Stern CE Compromised fronto-striatal functioning in HIV: an fMRI investigation of semantic event sequencing. Behav Brain Res 2008, 188:337-347.
119. Ernst T, Chang L, Jovicich J, Ames N, Arnold S Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 2002, 59:1343-1349.
120. Thomas JB, Brier MR, Snyder AZ, Vaida FF, Ances BM Pathways to neurodegeneration: effects of HIV and aging on resting-state functional connectivity. Neurology 2013, 80:1186-1193.
121. Ances BM, Sisti D, Vaida F, et al. Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 2009, 73:702-708.
122. Ances BM, Leontiev O, Perthen JE, Liang C, Lansing AE, Buxton RB Regional differences in the coupling of cerebral blood flow and oxygen metabolism changes in response to activation: implications for BOLD-fMRI. Neuroimage 2008, 39:1510-1521.
123. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008, 65:65-70.
124. Garvey L, Winston A, Walsh J, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 2011, 76:693-700.
125. Lanoy E, Guiguet M, Bentata M, et al. Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology 2011, 76:644-651.
126. McManus H, Li PC, Nolan D, et al. Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?. HIV Med 2011, 12:610-619.
127. Ellis R, Letendre S, Vaida R, et al. A randomized, controlled trial of a central nervous system-targeted ART strategy for HIV-associated neurocognitive disorders. 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA, USA; March 3-6, 2013. Abstract 3.
128. Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010, 74:1260-1266.
129. Robertson K, Liner J, Meeker RB Antiretroviral neurotoxicity. J Neurovirol 2012, 18:388-399.
130. Shikuma CM, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther 2012, 17:1233-1242.
131. Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis 2011, 204:1936-1945.
132. Yilmaz A, Verhofstede C, D'Avolio A, et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 2010, 55:590-596.
133. Wong HL, Chattopadhyay N, Wu XY, Bendayan R Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 2010, 62:503-517.
134. Clifford DB Human immunodeficiency virus-associated dementia. Arch Neurol 2000, 57:321-324.
135. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005, 293:2003-2011.
136. Sacktor N, Nakasujja N, Miyahara S, et al. Minocycline treatment for HIV-associated cognitive impairment in Uganda. Neurology 2011, 76:A23.
137. Letendre S, Marquie-Beck J, Ellis RJ, et al. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol 2007, 2:120-127.
138. Navia BA, Yiannoutsos CT, Change L, et al. ACTG 301: a phase II randomized, double-blind, placebo-controlled trial of memantine for AIDS dementia complex (ADC). American Academy of Neurology 53rd Annual Meeting; Philadelphia, PA, USA; May 4-11, 2001. Abstract A474-A5.
139. Anderson ER, Gendelman HE, Xiong H Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. J Neurosci 2004, 24:7194-7198.
140. Zhao Y, Navia BA, Marra CM, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials 2010, 11:59-67.
141. Simioni S, Cavassini M, Annoni JM, et al. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study. Neurology 2013, 80:553-560.
142. Routy JP, Tremblay CL, Angel JB, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 2012, 13:291-296.
143. Matalon S, Rasmussen TA, Dinarello CA Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 2011, 17:466-472.
144. Tong N, Sanchez JF, Maggirwar SB, et al. Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci 2001, 13:1913-1922.
145. Dou H, Birusingh K, Faraci J, et al. Neuroprotective activities of sodium valproate in a murine model of HIV-1 encephalitis. J Neurosci 2003, 23:9162-9170.
146. Ances BM, Letendre S, Buzzell M, et al. Valproic acid does not affect markers of human immunodeficiency virus disease progression. J Neurovirol 2006, 12:403-406.
147. Schifitto G, Peterson DR, Zhong J, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 2006, 66:919-921.
148. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012, 60(suppl 1):S1-18.
149. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 2005, 19:407-411.
150. Rempel HC, Pulliam L HIV-1 Tat inhibits neprilysin and elevates amyloid β. AIDS 2005, 19:127-135.
151. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L CSF amyloid β42 and tau levels correlate with AIDS dementia complex. Neurology 2005, 65:1490-1492.
152. Gisslén M, Blennow K, Brew B, et al. CSF neural marker profile distinguishes AIDS dementia complex from Alzheimer's disease. 15th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 3-6, 2008. Abstract 196.
153. 11C]PIB in a nondemented population. Potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
154. Ances BM, Benzinger TL, Christensen JJ, et al. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol 2012, 69:72-77.
155. Morgan EE, Woods SP, Letendre SL, et al. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol 2013, 19:150-156.
156. Corder EH, Robertson K, Lannfelt L, et al. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med 1998, 4:1182-1184.
157. Burt TD, Agan BK, Marconi VC, et al. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE e{open}4/e{open}4 genotype accelerates HIV disease progression. Proc Natl Acad Sci USA 2008, 105:8718-8723.
158. Joska JA, Combrinck M, Valcour VG, et al. Association between apolipoprotein E4 genotype and human immunodeficiency virus-associated dementia in younger adults starting antiretroviral therapy in South Africa. J Neurovirol 2010, 16:377-383.
159. Chang L, Andres M, Sadino J, et al. Impact of apolipoprotein E epsilon4 and HIV on cognition and brain atrophy: antagonistic pleiotropy and premature brain aging. Neuroimage 2011, 58:1017-1027.
160. Valcour V, Shikuma C, Shiramizu B, et al. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol 2007, 157:197-202.